The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of performance status (ECOG PS) on treatment outcome with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after first-line (1L) immune checkpoint inhibitor (ICI) combination therapy.
 
Christian Grohé
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Boehringer Ingelheim
Speakers' Bureau - Boehringer Ingelheim
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Thomas Wehler
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Janssen; MSD; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Janssen; MSD; Pfizer; Roche; Takeda
Research Funding - AstraZeneca; Boehringer Ingelheim
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Janssen; Pfizer
 
Sven Henschke
Stock and Other Ownership Interests - iShares Healthcare Innovation; Thermo Fisher Scientific
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Chugai Pharma; Merck Sharp & Dohme; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Chugai Pharma; Merck Sharp & Dohme; Roche
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Chugai Pharma; Merck Sharp & Dohme; Roche
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Chugai Pharma; Merck Sharp & Dohme; Roche
Other Relationship - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Chugai Pharma; Merck Sharp & Dohme; Roche
(OPTIONAL) Uncompensated Relationships - Boehringer Ingelheim
 
Ina Dittrich
Consulting or Advisory Role - AstraZeneca; BMS GmbH & Co. KG; Boehringer Pharma GmbH; Pfizer
 
Stefan Hammerschmidt
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Boehringer Ingelheim
 
Christoph Aulmann
No Relationships to Disclose
 
Tobias Dechow
No Relationships to Disclose
 
Conrad Schiefer
Honoraria - AstraZeneca; Boehringer Ingelheim; Chiesi; GlaxoSmithKline
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chiesi; GlaxoSmithKline
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chiesi; GlaxoSmithKline
Research Funding - Boehringer Ingelheim; Chiesi; GlaxoSmithKline
 
Ingo Zander
No Relationships to Disclose
 
Wolfgang Schuette
Honoraria - Boehringer Ingelheim; GlaxoSmithKline; MSD; Novartis; Roche; Sanofi
Consulting or Advisory Role - Boehringer Ingelheim; GlaxoSmithKline; MSD; Novartis; Roche; Sanofi
 
Judith Atz
Employment - Boehringer Ingelheim
 
Rolf Kaiser
Employment - Boehringer Ingelheim
Patents, Royalties, Other Intellectual Property - Boehringer Ingelheim